Institutional Investors in TG Therapeutics, Inc. (NASDAQ:TGTX) See US$145m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Institutional Investors in TG Therapeutics, Inc. (NASDAQ:TGTX) See US$145m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Key Insights
主要見解
- Given the large stake in the stock by institutions, TG Therapeutics' stock price might be vulnerable to their trading decisions
- A total of 11 investors have a majority stake in the company with 51% ownership
- Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
- 考慮到機構對股票的持有比例較大,tg therapeutics的股價可能會受到他們交易決策的影響
- 共有11名投資者擁有該公司的大部分股權,佔有51%的所有權。
- 分析師預測以及所有者數據可以給我們提供有關業務前景的強烈想法。
A look at the shareholders of TG Therapeutics, Inc. (NASDAQ:TGTX) can tell us which group is most powerful. With 76% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
看一下TG Therapeutics公司(納斯達克:TGTX)的股東,就能知道哪一群體最具影響力。機構擁有公司中最多的股份,佔比76%。換句話說,該群體面臨的上漲潛力(或下跌風險)最大。
Institutional investors was the group most impacted after the company's market cap fell to US$3.4b last week. Still, the 216% one-year gains may have helped mitigate their overall losses. We would assume however, that they would be on the lookout for weakness in the future.
納斯達克:TGTX所有權拆分2024年10月28日
Let's delve deeper into each type of owner of TG Therapeutics, beginning with the chart below.
讓我們深入研究TG Therapeutics每一種所有者,從下面的圖表開始。
What Does The Institutional Ownership Tell Us About TG Therapeutics?
機構所有權告訴我們有關TG Therapeutics的什麼?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。
TG Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of TG Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.
TG Therapeutics已經有機構投資者在股東名冊上持有股份。實際上,他們在公司擁有可觀的股份。這表明在專業投資者中有一定的信譽。但我們不能僅僅依賴於這個事實,因爲機構有時會做出糟糕的投資,就像每個人一樣。如果兩個大型機構投資者同時嘗試拋售股票,那麼很常見會看到股價大幅下跌。因此,值得檢查TG Therapeutics過去的收益軌跡(如下)。當然,也要記住還有其他因素需要考慮。
Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. TG Therapeutics is not owned by hedge funds. BlackRock, Inc. is currently the largest shareholder, with 15% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 9.5% and 5.7%, of the shares outstanding, respectively. Michael Weiss, who is the third-largest shareholder, also happens to hold the title of Chairman of the Board.
機構投資者擁有公司超過50%的股份,因此他們可能會強烈影響董事會的決定。tg therapeutics不被對沖基金擁有。目前,黑石集團是最大的股東,持有15%的股份。同時,第二和第三大股東分別持有淨流通股的9.5%和5.7%。而第三大股東麥克·韋斯(Michael Weiss)還兼任董事會主席。
Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership.
查看股東註冊表,我們可以看到前11大股東控制着該公司51%的股權,這意味着沒有單一的股東擁有多數股權。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
雖然仔細研究公司的機構持股數據是有意義的,但研究分析師對該股票的看法也是有意義的。有相當數量的分析師在跟蹤該股票,因此了解他們對於未來發展的總體看法可能會有所幫助。
Insider Ownership Of TG Therapeutics
TG Therapeutics的內部所有權
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
在不同國家,內部人員的定義可能會略有不同,但董事會成員始終是內部人員。管理層最終向董事會負責。然而,如果管理人員是創始人或CEO,那麼成爲執行董事會成員也是很常見的。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。
Our most recent data indicates that insiders own some shares in TG Therapeutics, Inc.. It is a pretty big company, so it is generally a positive to see some potentially meaningful alignment. In this case, they own around US$233m worth of shares (at current prices). If you would like to explore the question of insider alignment, you can click here to see if insiders have been buying or selling.
我們最近的數據顯示,一些內部持有tg therapeutics股票。 這是一家相當大的公司,因此看到一些潛在的有意義的對齊是積極的。 在這種情況下,他們擁有價值約23300萬美元的股票(以當前價格計算)。 如果您想探討內部持股問題,可以單擊此處查看內部人員是否一直在買入或賣出。
General Public Ownership
一般大衆所有權
The general public, who are usually individual investors, hold a 17% stake in TG Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
一般公衆,通常是個人投資者,在tg therapeutics持有17%的股份。 儘管這種所有權規模還不足以影響他們有利的政策決定,但他們仍然可以對公司政策產生集體影響。
Next Steps:
下一步:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.
我覺得查看公司的實際所有者非常有趣。但爲了真正獲得洞察力,我們需要考慮其他信息。
I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free.
我喜歡深入了解一家公司過去的表現。您可以免費訪問該互動圖表,了解其過去的盈利、營業收入和現金流。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一樣,可能希望考慮這家公司是否會增長或縮小。幸運的是,您可以查看此免費報告,顯示分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。